sclerosi multipla: la CONNESSIONE VASCOLARE

MAGNIMS consensus recommendation: Measure brain and spinal atrophy in MS

Posted: 10 Sep 2020 11:28 AM PDT

Readers of this blog have already learned about the importance of monitoring their gray matter.  Volume loss, or the shrinking of tissue, is also referred to as atrophy and neurodegeneration.  I explain this process in more depth here: link  The MRI measurement of atrophy has been proven to be more indicative of MS progression, when compared to white matter lesions.  (The fact that we still use a seventy year old mouse model to measure white matter lesions for MS drug efficacy boggles the mind.)  This paper advises that MS specialists look at other MRI markers to understand how treatments might be impacting loss of tissue and MS progression.

A consortium of international MS experts published this review earlier in the year, right before COVID, and I missed it.  It was not sponsored by any specific drug company.  The MAGNIMS study group (Magnetic Resonance in Imaging in MS) was comprised of MS experts from seven countries.  I highly recommend discussing this research with your doctor, to make sure you unde

 Continua:⬇️ http://ccsviinms.blogspot.com/?m=1

google.com, pub-0399915301528270, DIRECT, f08c47fec0942fa0